ArticleJAMA2017
NSAIDs for Chronic Low Back Pain.
Article in JAMA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Systematic review of guideline-recommended medications prescribed for treatment of low back pain.Chiropractic & manual therapies · 2022Pooled it
- Open-Label Placebo Injection for Chronic Back Pain With Functional Neuroimaging: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Addition of Celebrex and Pregabalin to Ropivacaine for Posterior Spinal Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial.Drug design, development and therapy · 2021Trial
- Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS).Pain medicine (Malden, Mass.) · 2020Trial
- Trial
- Exploring salivary metabolites as biomarkers in chronic craniofacial and orofacial pain: a metabolomic analysis.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Polysaccharide-based biomaterials for regenerative therapy in intervertebral disc degeneration.Materials today. Bio · 2025Review
- Drug retention after intradiscal administration.Drug delivery · 2024Article
- Neuronal Panx1 drives peripheral sensitization in experimental plantar inflammatory pain.Military Medical Research · 2024Article
- 5-Bromo-2-(phenyl-amino)-benzoic acid.IUCrData · 2024Article
- The importance of setting and therapeutic relationships when delivering chiropractic care to those living with disadvantage.Chiropractic & manual therapies · 2022Observational
- Amine Functionalized Trimetallic Nitride Endohedral Fullerenes: A Class of Nanoparticle to Tackle Low Back/Leg Pain.ACS applied bio materials · 2022Article
- Sex-Specific Pharmacotherapy for Back Pain: A Proof-of-Concept Randomized Trial.Pain and therapy · 2021Article
- Review
- Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 12-month results.Regional anesthesia and pain medicine · 2021Article
- Prospective Evaluation of Local Sustained Release of Celecoxib in Dogs with Low Back Pain.Pharmaceutics · 2021Article
- Acute low back pain: diagnosis and management.Singapore medical journal · 2021Article
- [Analysis of anxiety, depression and related factors in patients with chronic lumbocrural pain before minimally invasive surgery].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020Article
- Are Opioids Needed to Treat Chronic Low Back Pain? A Review of Treatment Options and Analgesics in Development.Journal of pain research · 2020Review
- Multimorbidity and functional impairment-bidirectional interplay, synergistic effects and common pathways.Journal of internal medicine · 2019Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical Question: Are nonsteroidal anti-inflammatory drugs (NSAIDs) associated with greater pain relief than placebo, other drugs, and nondrug treatments for patients with chronic low back pain? Bottom Line: Compared with placebo, NSAIDs are associated with a small but significant improvement in pain and disability in patients with chronic low back pain, although this difference became nonsignificant when studies with high risk for bias were excluded. The associated benefits were smaller than the minimal clinically important difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.